SavedAdd your journal

Journals / Journal of Surgery and Medicine / 2022 / Cilt: 6 - Sayı: 4

The effects of combined hydroxychloroquine and azithromycin therapy on QRS wave in COVID-19 patients

Ajar KOÇAK
Ayhan COŞGUN
Dilek KARAMANLIOĞLU
Mustafa Hamidullah TÜRKKANI
Pages
483–487
Publication Date
2022-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Among study participants, QRS duration was significantly prolonged after treatment with hydroxychloroquine and azithromycin (81.14 (9.11) versus 85.5 (10.48) ms [P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aim: Hydroxychloroquine and azithromycin are frequently used for the treatment of coronavirus disease 2019 (COVID-19).
📊
Key Findings & Data:The use of these medications increases the risk of adverse cardiovascular events.
💡
Conclusion & Impact:Results: Among study participants, QRS duration was significantly prolonged after treatment with hydroxychloroquine and azithromycin (81.14 (9.11) versus 85.5 (10.48) ms [P
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Arrhythmia · Azithromycin · COVID-19

Abstract

Background/Aim: Hydroxychloroquine and azithromycin are frequently used for the treatment of coronavirus disease 2019 (COVID-19). The use of these medications increases the risk of adverse cardiovascular events. The aim of our study was to investigate the effects of these drugs on the arrhythmogenic electrocardiographic (ECG) markers, QRS duration, and QRS dispersion, and also to evaluate gender differences with respect to these effects. Methods: Between March and June 2020, 107 (54 males, 53 females) patients admitted to our hospital’s isolation ward with COVID-19 diagnosis with no history, risk factors, or clinical findings of cardiovascular diseases were included in this prospective cohort study. All participants had a mild illness, and none of them required intensive care unit admission. ECGs of the patients were recorded before starting treatment with combined hydroxychloroquine and azithromycin, and a second ECG was recorded on the next morning following the last dose of the treatment. All ECGs were evaluated by two blinded cardiologists in terms of QRS duration and dispersion. Results: Among study participants, QRS duration was significantly prolonged after treatment with hydroxychloroquine and azithromycin (81.14 (9.11) versus 85.5 (10.48) ms [P

🔖

Cite This Article

KOÇAK, A., COŞGUN, A., KARAMANLIOĞLU, D., TÜRKKANI, M. H. (2022). The effects of combined hydroxychloroquine and azithromycin therapy on QRS wave in COVID-19 patients. Journal of Surgery and Medicine, Cilt: 6 - Sayı: 4, 483–487. https://ajindex.com/articles/779676

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33
  2. World Health Organization. COVID-19 Situation Report 51. Geneva, Switzerland 2020: (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 dated 11/03/2020
  3. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949
  4. Aggarwal G, Henry BM, Aggarwal S, Bangalore S. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. Am J Cardiol. 2020 Aug 1;128:147-50
  5. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace. 2014 Jan;16(1):101-8
  6. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5
  7. Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007 Dec;30(12):1579-82
  8. Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016 Jan;68(1):184-90. doi: 10.1002/art.39402. PMID: 26316040
  9. Fleet JL, Shariff SZ, Bailey DG, Gandhi S, Juurlink DN, Nash DM, et al. Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. BMJ Open. 2013 Jul 11;3(7):e002857
  10. Chávez-González E, Rodríguez Jiménez AE, Moreno-Martínez FL. QRS duration and dispersion for predicting ventricular arrhythmias in early stage of acute myocardial infraction. Med Intensiva. 2017 Aug-Sep;41(6):347-55
  11. Jain R, Gautam S, Wu C, Shen C, Jain A, Giesdal O, et al. Prognostic implications of QRS dispersion for major adverse cardiovascular events in asymptomatic women and men: the Multi-Ethnic Study of Atherosclerosis. J Interv Card Electrophysiol. 2019 Oct;56(1):45-53
  12. Gunay S, Caliskan S, Sigirli D, Sahin E. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromyci